Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Department of Medicine, Harvard Medical School, Boston, MA.
Blood. 2023 Oct 5;142(14):1248-1252. doi: 10.1182/blood.2023021429.
In 2 complementary Letters to Blood, Karschnia et al and Graham et al provide new insights into the neurological toxicities that are observed with B-cell maturation antigen–directed chimeric antigen receptor T-cell treatment for multiple myeloma, identifying a frequency of immune effector cell–associated neurotoxicity syndrome (ICANS) that exceeds 40%. Severe ICANS is identified in 8% of patients in this real-world series. Outcomes were generally favorable, although the authors describe rare, late Parkinsonism-like hypokinetic movement disorders (also known as movement and neurocognitive toxicities) post-ICANS in 2 patients.
在《Blood》杂志的 2 封补充信件中，Karschnia 等人和 Graham 等人提供了多发性骨髓瘤中 B 细胞成熟抗原导向嵌合抗原受体 T 细胞治疗所观察到的神经毒性的新见解，确定了细胞相关性神经毒性综合征（ICANS）的频率超过 40%。在这个真实世界的系列中，有 8%的患者出现严重的 ICANS。尽管作者描述了 2 例患者在发生 ICANS 后出现罕见的迟发性帕金森样运动障碍（也称为运动和神经认知毒性），但结果通常是有利的。
